Hathorn KE, Chan WW, Lo WK. Role of gastroesophageal reflux disease in lung transplantation. World J Transplant 2017; 7(2): 103-116 [PMID: 28507913 DOI: 10.5500/wjt.v7.i2.103]
Corresponding Author of This Article
Walter W Chan, MD, MPH, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, United States. wwchan@partners.org
Research Domain of This Article
Transplantation
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Transplant. Apr 24, 2017; 7(2): 103-116 Published online Apr 24, 2017. doi: 10.5500/wjt.v7.i2.103
Role of gastroesophageal reflux disease in lung transplantation
Kelly E Hathorn, Walter W Chan, Wai-Kit Lo
Kelly E Hathorn, Division of Internal Medicine, Brigham and Women’s Hospital, Boston, MA 02115, United States
Walter W Chan, Wai-Kit Lo, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital, Boston, MA 02115, United States
Walter W Chan, Wai-Kit Lo, Harvard Medical School, Boston, MA 02115, United States
Author contributions: All authors contributed to this manuscript.
Conflict-of-interest statement: The authors do not report any conflict of interests and have no financial disclosures relevant to the subjects of the manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Walter W Chan, MD, MPH, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, United States. wwchan@partners.org
Telephone: +1-617-7326389 Fax: +1-617-5250338
Received: August 25, 2016 Peer-review started: August 26, 2016 First decision: October 20, 2016 Revised: January 15, 2017 Accepted: February 8, 2017 Article in press: February 13, 2017 Published online: April 24, 2017
Core Tip
Core tip: Gastroesophageal reflux disease (GERD) has been associated with increased morbidity in lung transplant patients through a proposed pathway of reflux, aspiration, immunomodulation, and allograft injury, culminating in functional decline and rejection. This paper reviews the mechanisms of GERD-induced injury, describes outcome measures important in post-transplant assessment, and discusses the timing and modalities of diagnostic evaluation and management, including medical and surgical antireflux treatment, in optimizing post-transplant outcomes. A greater awareness of the harmful effects of GERD in the lung transplant population is important in the early diagnosis and management of such patients to minimize allograft injury and improve outcomes.
